Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.

Abstract

We conclude that in everyday practice, patients who require chronic NSAID therapy and who have specific clinical risk factors may benefit from misoprostol co-therapy.